Here are the 10-K annual reports from Beyond Air, Inc. (XAIR) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow XAIR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XAIR filings page.
Beyond Air, Inc. is a commercial-stage medical device and biopharmaceutical company focused on nitric oxide (NO) technologies. Its LungFit® platform generates NO from ambient air for respiratory uses, led by LungFit® PH, which has FDA premarket approval for treating persistent pulmonary hypertension of the newborn and CE mark approval in Europe for broader pulmonary hypertension indications.
The company is commercializing LungFit® PH in the U.S., has regulatory approvals in more than 27 countries outside the U.S. and EU, and distribution agreements covering over 40 countries. Pipeline devices include LungFit® PRO for viral pneumonias and bronchiolitis, and LungFit® GO for nontuberculous mycobacterial lung infections, all using high-concentration NO to target infections. Beyond Air’s majority-owned affiliate Beyond Cancer is developing ultra-high concentration NO (UNO) for solid tumors, having completed a Phase 1 trial, while NeuroNOS is advancing selective nNOS inhibitors for autism spectrum disorder and glioblastoma, with two FDA orphan drug designations. The company’s auditor has expressed substantial doubt about its ability to continue as a going concern, and management highlights the need for additional capital and strict compliance with its loan agreement.
Beyond Air (NASDAQ: XAIR) filed its Form 10-K Annual Report on June 29, 2025. The excerpt supplied consists almost entirely of XBRL taxonomy tags and entity identifiers, with no accompanying financial statements, narrative sections, risk factors, legal proceedings, or management discussion. Because the critical quantitative and qualitative disclosures normally included in a 10-K are absent from the provided content, no material information relevant to investors can be summarized from this excerpt.